Skip to main content
HRB Open Research logoLink to HRB Open Research
. 2020 Sep 23;3:12. Originally published 2020 Apr 1. [Version 2] doi: 10.12688/hrbopenres.13024.2

A protocol for a systematic review of clinical practice guidelines for recurrent miscarriage

Marita Hennessy 1,2,3,a, Rebecca Dennehy 1,2,3, Sarah Meaney 1,2,3,4, Declan Devane 2,5,6, Keelin O'Donoghue 1,2,3
PMCID: PMC7477641  PMID: 33005862

Version Changes

Revised. Amendments from Version 1

We have removed reference to “unpublished” after “grey” literature to avoid confusion as to the consistency of the search strategy and eligibility criteria outlined in the PICAR statement in Table 1. Grey literature will be used to identify CPGs that may meet the eligibility criteria for this review. We have added clarification about sources and use of grey literature to the information sources section:  “Searches of Web of Science, Scopus and Open Grey, as well as guideline repositories and the websites of professional bodies/organisations, will facilitate the identification of grey literature – such as conference proceedings and/or technical reports – which may contain information about potentially eligible CPGs.”

Abstract

Recurrent miscarriage (RM) was recently re-defined by the European Society of Human Reproduction and Embryology (ESHRE) as the loss of two or more consecutive pregnancies. Before this, and indeed still in some countries, RM was defined as three or more consecutive pregnancy losses. While the incidence of RM depends on the definition employed and population studied, it is generally accepted to affect 1-6% of women of reproductive age. Clinical practice guidelines (CPGs) for RM have been published by some professional organisations. While there are CPGs on miscarriage in Ireland, there are none concerning RM specifically. The aim of this systematic review is to identify, appraise and describe published CPGs for the management, investigation and/or follow-up of RM within high-income countries. Electronic databases (MEDLINE (Ovid ®; 1946), Embase ® (Elsevier; 1980), CINAHL Complete (EBSCOhost; 1994), Web of Science™ (Thomson Reuters), Scopus (Elsevier; 2004), and Open Grey (INIST-CNRS; 2011)), selected guideline repositories, and the websites of professional societies will be searched to identify CPGs, published within the last 20 years, for potential inclusion. Two reviewers will review abstracts and full texts independently against the eligibility criteria. Characteristics and recommendations of included CPGs will be extracted by one reviewer and double-checked by another. Two reviewers will use the Appraisal of Guidelines for Research and Evaluation version 2 (AGREE II) instrument independently to assess the quality of the included CPGs. Narrative synthesis will be conducted to appraise and compare CPGs and their recommendations or guidance therein. The identification, appraisal and description of published CPGs in other high-income countries will be a valuable first step in informing efforts to promote the optimisation and standardisation of RM care.

Keywords: recurrent miscarriage, miscarriage, early pregnancy loss, systematic review, clinical guidelines, antenatal, care quality

Abbreviations

FDA: Food and Drug Association; ICH GCP: International Conference on Harmonisation Good Clinical Practice; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; WHO: World Health Organization

Introduction

Clinical trials are research studies that test the safety and efficacy of novel treatments and interventions. Their effects on the health outcomes of humans are evaluated prospectively ( WHO, 2020). Such medical interventions include drugs, cells (and other biological products), surgical procedures, medical devices, behavioural treatments, radiological procedures and measures for preventative care ( WHO, 2020). Findings from trials have the potential to change clinical practice. For this reason and to minimise harm to patients, trials must be conducted to a very high standard.

The Merriam-Webster Dictionary describes statistics as " a branch of mathematics dealing with the collection, analysis, interpretation, and presentation of masses of numerical data" ( Merriam-Webster Dictionary, 2020). To put this definition into context, it implies: refining the study design in order to efficiently address the study’s research hypothesis while minimising bias, defining data to be collected, appropriately analysing data collected, and interpreting results in such a way as to facilitate clinical decision making.

Clinical data management (CDM) facilitates the statistical aspects in a trial. CDM activity in a trial involves the appropriate collection, management, access to and cleaning of clinical research data. The integrity of statistical analysis in a trial ultimately depends on the quality of the data that is available for analysis ( Adams-Huet & Ahn, 2009; Krishnankutty et al., 2012; Nesbitt, 2004, p.135). The validity of a clinical research study is therefore not solely judged on its results, but also on how the study itself was designed and conducted ( Adams-Huet & Ahn, 2009). The key team members responsible for the quality of statistical outputs from a trial are statisticians (/biostatisticians), clinical data managers and principal investigators (PIs). It is important to note the importance of, not only their roles and responsibilities, but their qualifications, experience, and training and how they work with other team members, and the potential impact these may have on the statistics of a trial.

There is also a relationship between statistics and ethics in trials. Ethical issues can affect not only the design of a trial, but all stages. If the statistical considerations of a trial are inadequate, the research will be unethical. This misuse of statistics in the clinical research field may have consequences for trial participants ( Altman, 1980), and other resources, including researchers’ time and effort. It is also unethical to publish and disseminate statistical results that may be misleading ( Altman, 1980).

Therefore, it can be deduced that statistics play an important role in all aspects of a trial, from planning, design, conduct, analysis through to reporting and publication. There is a plethora of literature discussing statistical methodologies in trials from a mathematical perspective. Less has been written about the trial team and other resources and how these may be influencing the statistical planning, design, conduct, analysis and reporting of trial data. Therefore, there remains a gap in the literature that needs to be addressed; systematically reviewing articles to fully comprehend, collate, and thematically synthesise the factors influencing the statistical aspects of trials is required.

This protocol will describe the methodological details for:

  • conducting a comprehensive search for relevant articles,

  • applying justified inclusion and exclusion (eligibility) criteria,

  • evaluating and appraising the included studies,

  • thematically synthesising the findings of the included studies.

Research question

What are the factors influencing the statistical planning, design, conduct, analysis and reporting in trials?

Rationale and aim of this review

The aim of this systematic review is to identify and describe factors contributing to and influencing the planning, design, conduct, analysis and reporting of trials, from a statistical perspective.

Objectives

  • To construct a systematic search strategy incorporating the relevant elements at the centre of the research question,

  • To identify, evaluate and critically appraise peer-reviewed literature (and relevant non-peer reviewed sources) that discuss factors contributing to the statistical aspects of a trial,

  • To develop an explanatory framework through a narrative thematic synthesis, for how these factors may influence the statistical planning, design, conduct, analysis and reporting of trials,

  • To present recommendations (based on the findings of this review) for how the statistical aspects of trials can be improved.

Methods

The protocol for this systematic review is not deemed eligible for registration in the PROSPERO database, as the outcome of this review is not a health-related one. This systematic review will investigate aspects of a trial methodological nature and will not investigate specific outcomes of a clinical relevance.

This protocol follows the PRISMA-P (Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols; Moher et al., 2015) guidelines. The PRISMA-P checklist can be found in Figshare ( Zaki et al., 2020c).

Criteria for considering studies for this review

Phenomenon of interest. The phenomenon of interest are the factors influencing the statistical planning, design, conduct, analysis or reporting of trials.

Papers will be included if they discuss any one or more of the following factors:

  • Roles, responsibilities, and tasks of key team members responsible for the statistical elements of the planning, design, conduct, analysis and reporting of trials

  • Qualifications, training, knowledge, experience and professional development of key team members responsible for the statistical planning, design, conduct, analysis and reporting of trials

  • Processes of communication and collaboration between key team members, and with others, responsible for the statistical planning, design, conduct, analysis and reporting of trials

Sources that do not meet the eligibility criteria will be excluded. If the key term 'trial' is not included in the full text, the article is not included in the final stage of the screening process.

While novel statistical methodologies, for example novel trial designs, can contribute to the statistical aspects of a trial, the focus of this review is on other factors influencing the planning, design, conduct, analysis and reporting of a trial.

Articles will be excluded if they focus solely on:

  • Pre-clinical research studies (animal/non-human studies)

  • Evaluation of effectiveness of an intervention for the prevention or treatment or clinical diseases/conditions

  • Cost-effectiveness articles or ones of a health economics perspective, not influencing the statistics of a trial

  • Regulatory articles, with no reference to factors influencing the statistical planning, design, conduct, analysis or reporting of randomised trials

  • Statistical theory

Types of studies. We will include all primary studies of any study design including studies that collect or analyse primary data through means of a secondary analysis. A preliminary scope of the literature revealed a lack of empirical literature in this field and therefore we will also include discussion/commentary papers.

Search methodology

Keyword search terms are informed by conducting a preliminary scope of the literature. The search strategy for this review is created and refined with the assistance of an information specialist (health sciences liaison librarian), experienced in systematic reviews. Key words are first identified, followed using controlled vocabulary search terms in individual databases.

The SPICE (Setting – Perspectives – Intervention – Comparison – Evaluation) framework is considered to be the best fit for the search strategy required in this systematic review, as the individual search features are suitable for the type of search in this review (see below). Other frameworks such as PICO (Population-Intervention-Comparison-Outcome), SPIDER (Sample-Phenomenon of Interest-Design-Evaluation-Research Type) and CIMO (Context-Intervention-Mechanism-Outcome) ( Booth, 2016) were considered but not deemed appropriate. The search strings (for S, P, I and E) can be found in Table 1 below. An optional search string, Comparison (C), is not included, as the aim is not to compare interventions or study designs but to extract information from each article.

Table 1. Keyword search terms.

Feature Search Terms
Setting (S) "clinical research"
Perspective (P) Statistician* OR biostatistician* OR "data manager*" OR investigator* OR "trial team*"
OR "clinical research team*" OR "statistics team*" OR "data management team*"
Intervention (I) "clinical trial*" OR trial OR trials
Evaluation (E) Statistics OR biostatistics OR data OR statistical OR planning OR design OR conduct OR
analysis OR analyses OR reporting

While the Setting (S) of the search terms is "clinical research", the Intervention (I) and focus of the review is on trials, not other clinical studies such as observational research. With regards to the Evaluation (E), the key elements from the research question (planning, design, conduct, analysis (or the plural ‘analyses’) and reporting) are included as these are the aspects to be evaluated and from where the relevant factors can be extracted. As statistics is the central phenomenon of this systematic review, the terms ‘statistics’ and ‘statistical’ are crucial. An alternative term for statistics, ‘biostatistics’ is included to ensure articles that mention this term instead of ‘statistics’ are not missed. Similarly, the search term ‘data’ is included to retrieve articles discussing data aspects that may influence the statistics of a trial.

Within each of the search term features, the keywords are combined using the ‘OR’ Boolean operators between them. This allows for broadening the search. Methods used to narrow the search while also using the Boolean operator includes the concept ‘AND’ between the features (see Table 1). Before the search is run in its entirety, search terms are individually assessed and run through the databases.

A systematic literature search is performed on the following electronic databases: PubMed NCBI, Web of Science, PsycINFO and CINAHL. This search in the bibliographic databases retrieves peer reviewed literature.

A pre-defined set of controlled vocabulary terms are used in the individual databases. These terms index, describe and categorise sources of information and ensures a comprehensive search in the databases. In the CINAHL database, such controlled vocabulary terms are known as 'Subject Headings'. In PubMed, the Advanced Search Builder finds alternative terms used by that database to describe a term. Such terms are known as MeSH (Medical Subject Headings). The list of controlled vocabulary terms in the PyscINFO database are known as the 'Thesaurus of Psychological Index Terms'. Web of Science is the only database included in this search strategy that does not have controlled vocabulary terms. If controlled vocabulary terms are appropriate and relevant, they are included for that database. Articles of interest retrieved in the preliminary scope of the literature are also used to locate MeSH terms of relevance in PubMed. These controlled vocabulary terms, while often the same as the original keyword search terms, are included to maximise the retrieval of potentially relevant articles. Individual MeSH/controlled vocabulary/thesauri terms from the individual databases can be found in Extended Data ( Zaki et al., 2020a).

To ensure a comprehensive search is conducted, the review is not limited geographically and so there are no restrictions on the locations/countries where articles are published.

The searches are also not limited by publication date. No database filters or restrictions are placed on gender or age of participants discussed in the articles. Due to limited translation resources, searches are limited to only include articles written in English. This systematic review is limited to peer-reviewed articles retrieved in the bibliographic databases and non-peer reviewed sources from the grey literature.

Information sources

While it is expected that most of the articles relevant for this systematic review can be obtained from the systematic bibliographic database search discussed, important sources may also be retrieved from grey searches. This search will therefore retrieve unpublished or non-peer reviewed literature sources. Open Grey EU is the grey literature database that will be used in this review. Backwards citation screening will also be conducted in this review. Relevant articles from the reference list of included articles, that meet the eligibility criteria, are included.

Guidelines relevant to the scope of the review are also important sources of information. Guidelines that will be included in this systematic review are:

The FDA, PSI, ICH GCP, ASA and CONSORT websites will be listed as professional organisations.

If additional information (not explicitly stated in the articles) is required, direct contact will be made with the study authors of the articles.

Data collection and analysis

Selection of studies. Two reviewers (MZ and LOS) will independently screen title and abstracts against the inclusion criteria. Disagreements will be resolved through discussion with a third reviewer (EM). The full text of papers included at title and abstract stage will also be assessed by two reviewers with recourse to a third (EM) should disagreements occur. A summarised synthesis will be provided of reasons all papers at full text stage were excluded.

Data extraction and management. Citations from database searches will be imported into EndNote and then merged and de-duplicated. Microsoft Excel will be used for data extraction.

Key characteristics and important features of the included articles will be extracted using a previously piloted structured data extraction form, in Microsoft Excel (template provided in Extended Data ( Zaki et al., 2020b)). In brief, this file presents the key features (‘data items’, in accordance with PRISMA-P) that will be extracted from the full text of the included articles. 10–20% of the data extraction will be checked for accuracy and thoroughness by a second researcher (EM).

Quality assessment

Once the researcher is aware of the types of articles to be included in the systematic review, it will then be decided whether the Critical Appraisal Skills Programme ( CASP, 2020) checklists or Mixed Methods Appraisal Tools ( MMAT, 2018) will be used to assess the quality of included articles. This will determine the strength of the body of evidence. The results of this appraisal will then be used to inform the synthesis and the interpretation of the results as well as the discussion of the findings of this review.

Data analysis and synthesis

As this review is not aiming to assess the risk of bias in any particular intervention or appraise the methodological quality of trials, the data analysis and synthesis will be limited to a thematic/narrative synthesis approach. While quantitative articles will be included in the review, their quantitative outcomes will not be assessed for heterogeneity or quantitatively synthesised in the form of a meta-analysis. There is also no planned assessment for meta-biases in the studies that are included in this review.

The aim of the data extraction, analysis and synthesis process is to extract factors influencing statistics, statistical processes, statistical interactions, and other statistical aspects in all stages of a trial. For this review, ‘factors’ can be defined as any element impacting, influencing, or contributing to any aspect of statistical planning, design, conduct, analysis and reporting in trials. A narrative thematic synthesis approach will be used to collate and describe the key information from all included sources. This approach has been used to analyse data and information extracted from both quantitative and qualitative studies ( Ryan et al., 2018).

Each stage of the analysis will be documented, as it is important to maintain transparency about how patterns within the data are identified, and to note any similarities or differences between sources. A coding frame will be presented. Similarities between codes will be identified, labelled and categorised into themes. Narrative descriptions of each theme will be provided. The final outcome of the thematic synthesis will be an overall account of the factors influencing the statistical planning, design, conduct, analysis and reporting in trials. Findings across articles will be synthesised and their meanings interpreted to answer the research question ( Ryan et al., 2018). Recommendations, where provided in the articles, will be emphasised. This review will also illuminate areas that are under-researched and where there is scope for future work. One reviewer (MZ) will undertake each of the steps of data extraction, synthesis and comparison of findings across information sources, and the work will be checked by a second researcher (EM). Feedback from a Research Studies Panel (MG, DD, EM) will be included in the final version of the systematic review.

Potential limitations

This review will only include studies that are published in English, due to limitations in translation resources. This could mean excluding other relevant information based on language barriers. Secondly, unpublished literature will not be included, possibly leaning towards an increased risk of publication bias in the research that is included.

Tracked and dated amendments

Any amendments to this protocol, including the dates of the amendments and justifications, will be documented and presented in a table in the systematic review publication.

Dissemination

The findings of the systematic review will be published in a peer-reviewed journal upon completion. This systematic review will be of interest not only to statisticians (biostatisticians) and data managers, but also PIs and other researchers and healthcare professionals working in the trials field.

Conclusion

The aim of this systematic review is to identify, describe and synthesise factors contributing to or influencing the statistical planning, design, conduct, analysis and reporting of trials. This will be conducted through a systematic search of the literature in four bibliographic databases: PubMed NCBI, Web of Science, PsycINFO and CINAHL. The eligibility criteria for including relevant articles is discussed along with the plans for critical appraisal, data extraction and data synthesis. The systematic review and thematic synthesis will be written in accordance with the PRISMA statement for systematic reviews. The data extraction and findings will be tabulated to present key features. Findings will then be synthesised narratively. The findings will inform healthcare professionals and researchers of key factors revolving around trial statistics and whether such factors can be addressed to better understand the methodology of trials.

Data availability

Underlying data

No data is associated with this article.

Extended data

Figshare Repository: Controlled Vocabulary Search Terms Bibliographic Databases, https://doi.org/10.6084/m9.figshare.12403421.v1, ( Zaki et al., 2020a).

Figshare Repository: Data Extraction Template for Systematic Review, https://doi.org/10.6084/m9.figshare.12403562.v1, ( Zaki et al., 2020b).

Reporting guidelines

Figshare: PRISMA-P checklist for “A protocol for a systematic review investigating factors influencing statistical planning, design, conduct, analysis and reporting of clinical trials”, https://doi.org/10.6084/m9.figshare.12264938.v1 ( Zaki et al., 2020c).

Data are available under the terms of the Creative Commons Zero “No rights reserved” data waiver (CC0 1.0 Public domain dedication).

Acknowledgements

The authors acknowledge the support of the Health Research Board and the Health Research Board – Trials Methodology Research Network and the School of Nursing, Midwifery & Health Systems, University College Dublin for providing the scholarship funding to the corresponding author for a doctoral study.

The authors also wish to thank Mr. Diarmuid Stokes, health sciences liaison librarian at the University College Dublin, for his assistance in creating and refining the search strategy for this systematic review.

Funding Statement

Health Research Board (HRB) Ireland [ILP-HSR-2019-011].

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

[version 2; peer review: 2 approved, 2 approved with reservations]

References

  1. Adams-Huet B, Ahn C: Bridging clinical investigators and statisticians: writing the statistical methodology for a research proposal. J Investig Med. 2009;57(8):818–824. 10.2310/JIM.0b013e3181c2996c [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Altman DG: 'Statistics and ethics in medical research: Misuse of statistics is unethical' BMJ. 1980;281(6249):1182–4. 10.1136/bmj.281.6249.1182 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Booth A: Searching for qualitative research for inclusion in systematic reviews: a structured methodological review. Syst Rev. 2016;5:74. 10.1186/s13643-016-0249-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Krishnankutty B, Bellary S, Kumar NBR, et al. : 'Data management in clinical research: An overview', Indian J Pharmacol. 2012;44(2):168–172. 10.4103/0253-7613.93842 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Moher D, Liberati A, Tetzlaff J, et al. : Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009;6(7):e1000097. 10.1371/journal.pmed.1000097 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Nesbitt LA: Clinical Research: What It Is and How It Works. MA, USA: Jones and Bartlett Publishers,2004;xvi–xviii. pp.135–136. Reference Source [Google Scholar]
  7. Ryan C, Hesselgreaves H, Wu O, et al. : Protocol for a systematic review and thematic synthesis of patient experiences of central venous access devices in anti-cancer treatment. Syst Rev. 2018;7(1):61. 10.1186/s13643-018-0721-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Zaki M, Galligan M, O'Sullivan L, et al. : Controlled Vocabulary Search Terms Bibliographic Databases. figshare.Figure.2020a. 10.6084/m9.figshare.12403421.v1 [DOI]
  9. Zaki M, Galligan M, O'Sullivan L, et al. : Data Extraction Template for Systematic Review. figshare.Figure.2020b. 10.6084/m9.figshare.12403562.v1 [DOI]
  10. Zaki M, Galligan M, O'Sullivan L, et al. : PRISMA-P-checklist Systematic Review Protocol - Statistical Factors in Clinical Trials.doc. figshare.Figure.2020c. 10.6084/m9.figshare.12264938.v1 [DOI]
HRB Open Res. 2020 Sep 21. doi: 10.21956/hrbopenres.14119.r27802

Reviewer response for version 1

Matthew Coleman 1, Sarah Bailey 1

This peer review report was updated on 22nd September 2020 to incorporate further comments from the reviewers. 

Matthew Coleman:

Summary

A few comments to help guide the authors. The vision is laudable however I am uncertain about the process especially in this highly emotive area.

Whilst the overall methods quote and follow national and international recommended methodology, the original challenge is made extremely complex by any number of human factors and biases. Current evidence is largely opinion based and confounded by bias and human factors. And given the distress caused by the disease these have sometimes been exaggerated. For example, the reasons behind the recent change in Rm definition, which might include as many as 6% of women, is complex and multi factorial and makes evaluating possible interventions difficult for the majority of women for whom the outlook is already consistent with women who have not experienced to consecutive miscarriages.

Understanding the psychology and reasons behind the recommendations would provide much more useful background for developing future guidelines which are rational fair and achievable.

Scope There appears to be some conflict in the defined scope of this review;

Scope:

  • Must have a primary/secondary focus on the investigation/treatment of RM.

  • Must be national/international in scope.

  • Covers any aspect of RM care and its organisation.

  • Must be clearly identified as a CPG.

  • Must be published.

Time span; given the rapid evolution of recommended managements in this particular area including recent and distant past guideline recommendations (as far back as 2000) any review is likely to produce significant inconsistencies related to change over time. Amalgamating them together will require some complexity to control for these changes, which are also destabilised by the paucity of data, bias and frequent personal opinion.

Sarah Bailey: 

The objective of this protocol for a systematic review of clinical practice guidelines (CPG) is to identify, appraise and describe published CPGs of the management, investigation and follow-up of recurrent miscarriage (RM) within high-income countries. The aim being to take the timely and important first step to promote consistent and evidence based care for couples with RM in Ireland.

The protocol is well-written and easy to follow and the proposed methodology is, overall, clearly described using recognised frameworks and tools to assist.   

Please see below comments;

Introduction:

  • In addition to highlighting that the definition of RM, with regards to number of miscarriages that constitute the term, varies from country to country, it would be useful to note at this point that actual term used to describe the condition can significantly vary between countries and CPGs – e.g. ESHRE uses term recurrent pregnancy loss (ESHRE 2017).

Protocol:

  • The PICAR statement provides a useful and thorough framework to guide the review of inclusion and exclusion criteria, as clearly demonstrated in Table 1.

  • Clarification is required of how the researchers plan to identify relevant ‘grey’ unpublished literature and I would advise the authors to make clear the exact range of information sources that will be utilised to locate CPGs concerning RM to allow a reproducible literature search.  However, the PICAR statement in Table 1, also identifies that unpublished CPGs will be excluded. This is confusing given the plan to locate unpublished literature sources and this inconsistency should be addressed. 

  • I was pleased to see the protocol was developed in conjunction with a Pregnancy Loss Patient Representative and encourage the prompt establishment of a PPI group to support this research.

Conclusion:   

I assume the overall aim of the systematic review is to develop a CPG on RM to promote consistent and standardized care for couples with RM in Ireland, but the actual planned outcome is not clearly articulated and it would be useful to have clarification of this.

Is the study design appropriate for the research question?

Partly

Is the rationale for, and objectives of, the study clearly described?

Yes

Are sufficient details of the methods provided to allow replication by others?

Yes

Are the datasets clearly presented in a useable and accessible format?

Not applicable

Reviewer Expertise:

Obstetric medicine, haematology and pregnancy, diabetes pregnancy, hypertension pregnancy. Clinical Specialist in Recurrent Miscarriage.

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above.

HRB Open Res. 2020 Sep 15. doi: 10.21956/hrbopenres.14119.r27846

Reviewer response for version 1

Emma Rasmark Roepke 1

The aim of this systematic review protocol is to identify and describe published clinical practice guidelines for management, diagnostics and/or follow-up of women with RM. The authors will use an electronic database search to identify published guidelines in English within the last 20 years in high-income countries.

This study aims to assess a standardisation of RM care. Overall, the protocol is well described with an appropriate study design.

There are some concerns:

  • The PICAR states that only published guidelines will be included though "grey litteature" will also be serached for. Can the authors explaine this further?

  • Why is GRADE system not used instead of AGREE?

  • How will "low quality" guidelines be compared with "high quality"? How will different quality be implented in the en result (a new guideline)?

  • What will the end results be from this expansive research? Is it a national guideline in Ireland?

Is the study design appropriate for the research question?

Partly

Is the rationale for, and objectives of, the study clearly described?

Yes

Are sufficient details of the methods provided to allow replication by others?

Yes

Are the datasets clearly presented in a useable and accessible format?

Yes

Reviewer Expertise:

Recurrent pregnancy loss

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

HRB Open Res. 2020 Sep 7. doi: 10.21956/hrbopenres.14119.r27847

Reviewer response for version 1

Jennifer Kaiser 1

This protocol outlines a systematic review of English language, high-income country CPGs for recurrent pregnancy loss in the first trimester. The intention is to identify and describe published CPGs in order to move towards standardization of management, investigation, and follow-up of RM. The strengths of this protocol include its registration with PROSPERO, utilization of a specialist librarian, and adherence to the PRISMA-P guidelines.

  • The "grey" literature is denoted as being "unpublished" in the protocol. However, in the PICAR statement, it states that unpublished material will be excluded. Please clarify this seeming inconsistency. Further detail on the "range of information sources" used to locate CPGs would improve reproducibility.

  • A lingering question is what the final product of this protocol will be. The aim is to identify, appraise, and describe CPGs with the intent of promoting standardization, but ultimately will this information be use to create a national CPG for Ireland? Or some other consensus statement? A clearer statement on its final uses would strengthen the rationale for this review further.

Is the study design appropriate for the research question?

Yes

Is the rationale for, and objectives of, the study clearly described?

Yes

Are sufficient details of the methods provided to allow replication by others?

Yes

Are the datasets clearly presented in a useable and accessible format?

Not applicable

Reviewer Expertise:

Early pregnancy loss, miscarriage management

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

HRB Open Res. 2020 Sep 23.
Marita Hennessy 1

Thank you for taking the time to review and provide feedback on our protocol paper.

Comment 1:

The "grey" literature is denoted as being "unpublished" in the protocol. However, in the PICAR statement, it states that unpublished material will be excluded. Please clarify this seeming inconsistency. Further detail on the "range of information sources" used to locate CPGs would improve reproducibility.

Response:

We have removed reference to “unpublished” after “grey” literature to avoid confusion between the search strategy and the PICAR statement. Grey literature will be used to identify CPGs that may be eligible for inclusion. We will use bibliographic databases (Web of Science, Scopus and Open Grey), as well as guideline repositories (detailed in Table 2) and the websites of professional bodies/organisations (detailed in Table 3), to identify grey literature including conference proceedings and/or technical reports. These, along with the other databases mentioned, comprise the full range of information sources used to locate CPGs. While search terms are presented in Table 4, the full search strategy will be published alongside the paper outlining the findings of this systematic review. 

We have added the following sentence to the “information sources” section to clarify what we mean by grey literature: “Searches of Web of Science, Scopus and Open Grey, as well as guideline repositories and the websites of professional bodies/organisations, will facilitate the identification of grey literature – such as conference proceedings and/or technical reports – which may contain information about potentially eligible CPGs.”

Comment 2:

A lingering question is what the final product of this protocol will be. The aim is to identify, appraise, and describe CPGs with the intent of promoting standardisation, but ultimately will this information be use to create a national CPG for Ireland? Or some other consensus statement? A clearer statement on its final uses would strengthen the rationale for this review further.

Response:

As noted in the protocol, this study is a first step in informing efforts to promote the optimisation and standardisation of RM care. This review is being conducted as part of a larger project titled “REcurrent miscarriage: Evaluating CURRENT services (RE:CURRENT)” which is looking at service provision in Ireland. The findings from the systematic review will be used by the RE:CURRENT Team to inform this evaluation; however, we did not detail this within the protocol as the findings of this systematic review will have relevance to the field in general, not just the RE:CURRENT Team.

HRB Open Res. 2020 May 18. doi: 10.21956/hrbopenres.14119.r27360

Reviewer response for version 1

Merel M J van den Berg 1

Summary

This systematic review identifies and describes published clinical practice guidelines for the management, diagnostics and/or follow-up of women with RM. This studies focuses on high-income countries. Electronic databases, selected guideline repositories and the websites of professional societies will be searched to identify guidelines within the last 20 years.

This study is the first step for the optimisation and standardisation of RM care.

Overall, the protocol is clearly described. The aim of the study is clear with an appropriate study design.

The only thing what is unclear for me is how the researchers will search for the so-called grey literature. They state that 'We will therefore use a range of information sources to locate CPGs concerning RM.' What do they mean by that? How will they do that? This needs more clarification.

Is the study design appropriate for the research question?

Yes

Is the rationale for, and objectives of, the study clearly described?

Yes

Are sufficient details of the methods provided to allow replication by others?

Partly

Are the datasets clearly presented in a useable and accessible format?

Yes

Reviewer Expertise:

Early pregnancy.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

HRB Open Res. 2020 Sep 23.
Marita Hennessy 1

Thank you for taking the time to review and provide feedback on our protocol paper.

Comment 1:

The only thing what is unclear for me is how the researchers will search for the so-called grey literature. They state that 'We will therefore use a range of information sources to locate CPGs concerning RM.' What do they mean by that? How will they do that? This needs more clarification.

Response:

Grey literature will be used to identify CPGs that may be eligible for inclusion. We will use academic databases (Web of Science, Scopus and Open Grey), as well as guideline repositories (detailed in Table 2) and the websites of professional bodies/organisations (detailed in Table 3), to identify grey literature including conference proceedings and/or technical reports. These, along with the other databases mentioned, comprise the full range of information sources used to locate CPGs. While search terms are presented in Table 4, the full search strategy will be published alongside the paper outlining the findings of this systematic review. 

We have added the following sentence to the “information sources” section to clarify what we mean by grey literature: “Searches of Web of Science, Scopus and Open Grey, as well as guideline repositories and the websites of professional bodies/organisations, will facilitate the identification of grey literature – such as conference proceedings and/or technical reports – which may contain information about potentially eligible CPGs.”

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Data Citations

    1. Zaki M, Galligan M, O'Sullivan L, et al. : Controlled Vocabulary Search Terms Bibliographic Databases. figshare.Figure.2020a. 10.6084/m9.figshare.12403421.v1 [DOI]
    2. Zaki M, Galligan M, O'Sullivan L, et al. : Data Extraction Template for Systematic Review. figshare.Figure.2020b. 10.6084/m9.figshare.12403562.v1 [DOI]
    3. Zaki M, Galligan M, O'Sullivan L, et al. : PRISMA-P-checklist Systematic Review Protocol - Statistical Factors in Clinical Trials.doc. figshare.Figure.2020c. 10.6084/m9.figshare.12264938.v1 [DOI]

    Data Availability Statement

    Underlying data

    No data is associated with this article.

    Extended data

    Figshare Repository: Controlled Vocabulary Search Terms Bibliographic Databases, https://doi.org/10.6084/m9.figshare.12403421.v1, ( Zaki et al., 2020a).

    Figshare Repository: Data Extraction Template for Systematic Review, https://doi.org/10.6084/m9.figshare.12403562.v1, ( Zaki et al., 2020b).

    Reporting guidelines

    Figshare: PRISMA-P checklist for “A protocol for a systematic review investigating factors influencing statistical planning, design, conduct, analysis and reporting of clinical trials”, https://doi.org/10.6084/m9.figshare.12264938.v1 ( Zaki et al., 2020c).

    Data are available under the terms of the Creative Commons Zero “No rights reserved” data waiver (CC0 1.0 Public domain dedication).


    Articles from HRB Open Research are provided here courtesy of Health Research Board Ireland

    RESOURCES